- Home
- ALF vs OMER Comparison
ALF vs OMER Comparison
Compare ALF & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALF
- OMER
- Stock Information
- Founded
- ALF 2024
- OMER 1994
- Country
- ALF United States
- OMER United States
- Employees
- ALF N/A
- OMER N/A
- Industry
- ALF
- OMER Biotechnology: Pharmaceutical Preparations
- Sector
- ALF
- OMER Health Care
- Exchange
- ALF NYSE
- OMER Nasdaq
- Market Cap
- ALF 379.1M
- OMER 397.1M
- IPO Year
- ALF 2024
- OMER 2009
- Fundamental
- Price
- ALF $10.52
- OMER $3.21
- Analyst Decision
- ALF
- OMER Strong Buy
- Analyst Count
- ALF 0
- OMER 5
- Target Price
- ALF N/A
- OMER $18.00
- AVG Volume (30 Days)
- ALF 211.2K
- OMER 808.8K
- Earning Date
- ALF 01-01-0001
- OMER 08-06-2025
- Dividend Yield
- ALF N/A
- OMER N/A
- EPS Growth
- ALF N/A
- OMER N/A
- EPS
- ALF 0.37
- OMER N/A
- Revenue
- ALF N/A
- OMER N/A
- Revenue This Year
- ALF N/A
- OMER N/A
- Revenue Next Year
- ALF N/A
- OMER $468.75
- P/E Ratio
- ALF $28.31
- OMER N/A
- Revenue Growth
- ALF N/A
- OMER N/A
- 52 Week Low
- ALF $9.96
- OMER $2.97
- 52 Week High
- ALF $10.60
- OMER $13.60
- Technical
- Relative Strength Index (RSI)
- ALF N/A
- OMER 34.64
- Support Level
- ALF N/A
- OMER $2.97
- Resistance Level
- ALF N/A
- OMER $4.06
- Average True Range (ATR)
- ALF 0.00
- OMER 0.26
- MACD
- ALF 0.00
- OMER 0.10
- Stochastic Oscillator
- ALF 0.00
- OMER 22.02
About ALF CENTURION ACQUISITION CORP
Centurion Acquisition Corp is a blank check company.
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.